
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
SGS has collaborated with Bavarian Nordic to develop a novel and differentiated challenge model for respiratory syncytial virus. This partnership brings both expertise and a view of wanting to bring a life changing therapy to the market. This new model will assist with the advancement of a universal vaccine candidate designed to induce protective immune responses against both subtypes (A & B) of RSV.
Read the full release






